Charles River Launches Novel IgY-based ELISA Kit
The kit is meant for use for the detection and quantitation of residual host cell protein.
Charles River Laboratories announced on Feb. 13, 2023 the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) kit for the detection and quantitation of residual host cell proteins (HCP) in Chinese hamster ovary (CHO)-based biotherapeutics.
The new HCP-ELISA kit leverages avian immunoglobulin Y (IgY) antibodies as the primary detection technology. These antibodies are derived from specific-pathogen-free chicken (SPF) eggs developed exclusively by AVS Bio. The HCP-ELISA kit builds upon Charles River’s HCP-GAPex service, increasing the efficiency and efficacy of HCP assay development.
“With more than 30 years of impurity testing experience, host cell protein assays are one of our core competencies,” said Kerstin Dolph, corporate senior vice president, biologics solutions, Charles River, in a company press release. “Building on that expertise to bring our inaugural kit to market was the next logical step to strengthen our Biologics Testing offering.”
Source: Charles River
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
